Zurich, 20 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: 
ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual 
report and its annual financial statements for the year 2021 on 26 June 2022 at the latest. As a company listed on SIX, Achiko is required to publish its annual report, together with the annual financial statements, within four months of the balance sheet date. Due to the Covid-19 pandemic, new staffing and training under difficult conditions in consequence of measures taken by several countries required a lot of management capacity. As a result, the publication of the annual report 2021, together with the annual financial statements and the audit report, will occur in the month of June 2022. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the annual report and the annual financial statements 2021. On 28 April 2022, SER granted Achiko the requested extension.  Achiko filed a second extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 30 May 2022, SER granted Achiko the second extension. Achiko filed a third extension request with SER regarding the publication of the annual report and the annual financial statements 2021.  On 3 June 2022, SER granted Achiko the third extension. On 10 June 2022, Achiko filed a fourth extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 10 June, SER granted Achiko the fourth extension. On 20 June 2022, Achiko filed a fifth extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 20 June, SER granted Achiko the fifth extension.  The delay is a function of the matters announced previously including continuity of operations in the second half of the financial year as a result of the Covid-19 pandemic and the higher than expected manual administrative workload, in particular regarding the auditory reconciliation documentation.   In addition, the Company’s CEO contracted Covid-19 during the calendar week 23/2022 limiting his ability to compile the relevant accounting documentation swiftly and interact with others in physical meetings.

As required by SER, Achiko hereby reprints para. I of SER’s respective decision: 

“The exemption application of Achiko (Issuer) dated 20 June 2022 requesting a fifth extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG until 26 June 2022 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):    

1. SIX Exchange Regulation AG reserves the right to suspend trading of the registered shares of the Issuer in case its 2021 annual report is  not  published  in  accordance  with  the  provisions on ad hoc publicity (Art. 53 of the Listing Rules [LR] in connection with the  Directive on Ad hoc Publicity [DAH]) and not filed with SIX Exchange Regulation AG until Sunday, 26 June 2022, 11.59 pm CET, at the latest.
2. Achiko is required to publish a notice in accordance with the provisions on ad hoc publicity (art. 53 LR  in  connection with the DAH)  concerning  this  decision until  Monday 20  June  2022, 23.59 am CET, at the latest. The notice must contain: 

• the unaltered reproduction of the wording of para. I. of this decision, placed in a prominent position; 

• the reasons for the application of the Issuer requesting a fifth extension of the deadline to  publish  its  2021  annual  report  and  to  file  such  report  with  SIX  Exchange Regulation AG.” 

The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and its annual financial statements for the year 2021. 

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Zurich, 10 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the year 2021 on 20 June 2022 at the latest. As a company listed on SIX Swiss Exchange, Achiko is required to publish its annual report, together with the annual financial statements, within four months of the balance sheet date.

Due to the Covid-19 pandemic, new staffing and training under difficult conditions in consequence of measures taken by several countries required a lot of management capacity. As a result, the publication of the annual report 2021, together with the annual financial statements and the audit report, will occur in the month of June 2022. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the annual report and the annual financial statements 2021. On 28 April 2022, SER granted Achiko the requested extension.  Achiko filed a second extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 30 May 2022, SER granted Achiko the second extension. Achiko filed a third extension request with SER regarding the publication of the annual report and the annual financial statements 2021.  On 3 June 2022, SER granted Achiko the third extension. Achiko filed a fourth extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 10 June, SER granted Achiko the fourth extension.  

The delay is a result of the matters previously announced including continuity of operations in the second half of the financial year as a result of the Covid-19 pandemic and the higher than expected manual administrative workload, in particular regarding the auditory reconciliation documentation.

Ahead of the Audited Financial Statements being published, the Company advises the following unaudited key financial figures:

In an earlier announcement on 19 May 2022, the Company reported an unaudited adjusted EBITDA loss of USD$5.258m and noted the adjustments of stock-based items had yet to be completed.   The final unaudited stock-based payments (share options, interest, financing costs, etc.) is USD$2.711m and includes an interest component of USD$0.835m.  The difference between the earlier reported adjusted EBITDA loss and the final unaudited EBITDA loss of USD$8,295m is attributable to: (1) USD$0.713m in costs associated with a Swiss subsidiary and a result of retrieval of accounting records; (2) re-inclusion of director’s fees of USD$0.500m (the Board of Directors and Advisory Board fees are substantially outstanding, unpaid and majority subordinated); (3) USD$1.876m of non interest Stock based payments; and (4) other miscellaneous adjustments. 

In all, the operating losses in 2021 compared to the prior year, reflect continued investment in bringing AptameX™, to commercialisation in a challenging operating environment, and substantial cost reductions in the second half of 2021.  Given the Company’s position at year end, it’s focus was on commercialising AptameX.  To that goal, and subsequent to the end of the reporting period, the company has successfully reported in-vivo performance results of AptameX indicating a highly sensitive and highly specific test at low viral loads for Covid-19, sales and marketing agreements with the largest Islamic organisation in the world, Nahdlatul Ulama in Indonesia, updated production contracts with production partner Indofarma in Indonesia, obtaining a CE Mark enabling the Company to be able to sell AptameX in Europe, and has accepted USD$1.25m in financing in a range of equity and debt instruments.

As required by SER, Achiko hereby reprints para. I of SER’s respective decision:

“The exemption application of Achiko (Issuer) dated 10 June 2022 requesting a fourth extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG until 20 June 2022 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):

1. SIX Exchange Regulation AG reserves the right to suspend trading of the registered shares of the Issuer in case its 2021 annual  report  is  not  published  in  accordance  with  the  provisions on ad hoc publicity (Art. 53 of the Listing Rules [LR] in connection with the  Directive on Ad hoc Publicity [DAH]) and not filed with SIX Exchange AG until Monday, 20 June 2022, 11.59 pm CET, at the latest.
2. Achiko is required to publish a notice in accordance with the provisions on ad hoc publicity (art. 53  LR  in  connection with the DAH)  concerning  this  decision until  Friday, 10  June  2022, 23.59 am CET, at the latest. The notice must contain:

• the unaltered reproduction of the wording of para. I. of this decision, placed in a prominent position; 

• the reasons for the application of the Issuer requesting a fourth extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG.

• the updated unaudited key figures such Net Revenues, EBITDA, EBIT, profits/loss, balance sheet total, equity etc. for the annual results 2021.” 

The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and its annual financial statements for the year 2021. 

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Zurich, 6 June 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the year 2021 on 10 June 2022 at the latest. As a company listed on SIX, Achiko is required to publish its annual report, together with the annual financial statements, within four months of the balance sheet date. Due to the Covid-19 pandemic, new staffing and training under difficult conditions in consequence of measures taken by several countries required a lot of management capacity. As a result, the publication of the annual report 2021, together with the annual financial statements and the audit report, will occur in the month of June 2022. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the annual report and the annual financial statements 2021. On 28 April 2022, SER granted Achiko the requested extension.  Achiko filed a second extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 30 May 2022, SER granted Achiko the second extension. Achiko filed a third extension request with SER regarding the publication of the annual report and the annual financial statements 2021.  On 3 June 2022, SER granted Achiko the third extension. The delay is a function of the matters announced previously including continuity of operations in the second half of the financial year as a result of the COVID 19 pandemic and the higher than expected manual administrative workload, in particular regarding the auditory reconciliation documentation.

As required by SER, Achiko hereby reprints para. I of SER’s respective decision:

“The exemption application of Achiko (Issuer) dated 30 May 2022 requesting a third extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG until 10 June 2022 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):   

1. SIX Exchange Regulation AG reserves the right to suspend trading of the registered shares of the Issuer in case its 2021 annual report is not published in accordance with the provisions on ad hoc publicity (Art. 53 of the Listing Rules [LR] in connection with the Directive on Ad hoc Publicity [DAH])
2. Achiko is required to publish a notice in accordance with the provisions on ad hoc publicity (art. 53 LR in connection with the DAH) concerning this decision until Monday 6 June 2022, 11.59 pm CET, at the latest. The notice must contain:
   • the unaltered reproduction of the wording of para. I. of this decision, placed in a prominent position;
   • the reasons for the application of the Issuer requesting an extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG.”

The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and its annual financial statements for the year 2021.

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Zurich, 31 May 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the year 2021 on 6 June 2022 at the latest. As a company listed on SIX, Achiko is required to publish its annual report, together with the annual financial statements, within four months of the balance sheet date. Due to the Covid-19 pandemic, new staffing and training under difficult conditions in consequence of measures taken by several countries required a lot of management capacity. As a result, the publication of the annual report 2021, together with the annual financial statements and the audit report, will occur in the month of June 2022. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the annual report and the annual financial statements 2021. On 28 April 2022, SER granted Achiko the requested extension.  Achiko filed a second extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 30 May 2022, SER granted Achiko the second extension.

Achiko does not expect that there will be any material difference from the unaudited figures published on 19 May 2022 to the figures to be published in the audited annual financial statements for the year ended 31 December 2021.

As required by SER, Achiko hereby reprints para. I of SER’s respective decision:

“The exemption application of Achiko (Issuer) dated 30 May 2022 requesting a second extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG until 6 June 2022 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):  

1. SIX Exchange Regulation AG reserves the right to suspend trading of the registered shares of the Issuer in case its 2021 annual report is not published in accordance with the provisions on ad hoc publicity (Art. 53 of the Listing Rules [LR] in connection with the Directive on Ad hoc Publicity [DAH]) and not filed with SIX Exchange Regulation AG until Monday, 6 June 2022, 11.59 pm CET, at the latest
2. Achiko is required to publish a notice in accordance with the provisions on ad hoc publicity (art. 53 LR in connection with the DAH) concerning this decision until Tuesday, 31 May 2022, 7.30 am CET, at the latest. The notice must contain:
   • the unaltered reproduction of the wording of para. I. of this decision, placed in a prominent position;
   • the reasons for the application of the Issuer requesting an extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG.”

The next annual general meeting will take place on 27 June 2022.

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

• Buranto AG provided a CHF 250,000 loan facility and existing strategic investor Negma Group provided a CHF 1.0 million loan facility
• Derek Brandt, co-owner of Buranto AG, joins Achiko’s Advisory Board
• Funds to be used for production in Indonesia and initiate production in Taiwan to meet global demand for AptameX^TM which obtained a CE Mark earlier this month

Zurich, 25 May 2022: Ad hoc announcement pursuant to Art. 53 LR –Achiko AG (SIX: ACHI; OTCQB:

ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces the completion of a CHF 1.25 million financing with strategic investors Buranto AG and Negma Group.

Buranto AG, a Swiss based company co-owned by Derek Brandt, has provided a loan facility of CHF 250,000 with the full amount drawn immediately.  Derek Brandt will also join Achiko’s Advisory Board.  Derek Brandt has more than 20 years general management and business development experience in MedTech, IVD, Pharma / Biotech and the Life Science Industry. Previous experience includes having served as Head of Clinical Development Group for Roche Diabetes and CEO of Sensile Medical.

Negma Group, one of the Company’s existing strategic shareholders, has provided a loan facility of CHF 1.0 million, with an immediate financing of CHF 500,000 and the balance to be drawn within the next 60 days.

“We’re excited and grateful to our shareholders, old and new”, said Steven Goh, CEO of Achiko AG.  “Covid-19 is going to be with us a long time and the unique performance and customer experience characteristics of the company.  With this financing we’re in a position to drive sales and do some good.”

The financing follows the Marketing and Sales agreement with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta (“PWNU”), the Jakarta District of Nahdlatul Ulama (“NU”), the largest Islamic organisation in the world and initiate global production in Taiwan to respond to interest in AptameX™ for expansion beyond Indonesia since obtaining a CE mark earlier this month.

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and AptameX received the CE mark in the European Union in May 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX^TM and companion health apps via its digital mobile health technology division, Teman Sehat^TM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.